COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Completed · Phase 1

Conditions studied: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC

In brief

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Key facts

Study ID

NCT04354246

Run by

Compugen Ltd

People needed

94

Starts

2020-03-31

Expected to finish

2026-04-01

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Florida Cancer Specialists — Sarasota, Florida, United States
• Massachusetts General Hospital. — Boston, Massachusetts, United States
• START Midwest. — Grand Rapids, Michigan, United States
• The Ohio State University Comprehensive Cancer Center. — Columbus, Ohio, United States
• The University of Tennessee WEST Cancer Center. — Memphis, Tennessee, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• MD Anderson Cancer Center. — Houston, Texas, United States
• The START Center for Cancer Care. — San Antonio, Texas, United States
• Froedtert & Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.